|
TAK-779, non-peptide antagonist for C-C chemokine receptor type 5 (CCR5) receptor
|
|
|
TAK-779 was the first non-peptide antagonist for C-C chemokine receptor type 5 (CCR5) receptor that
effectively blocks the cell entry of R5-type HIV [1]. TAK-779 is also an antagonist of CCR2b and CXC
chemokine receptor 3 (CXCR3) [2]. Treatment with TAK-779 reduced incidence and severity of experimental
autoimmune encephalomyelitis due to reduced migration of inflammatory cells into the CNS [3].
|
Details
|
Chemical Formula:
|
|
C33H39N2O2.Cl
|
|
CAS No.:
|
|
229005-80-5
|
|
Molecular Weight:
|
|
531.14
|
|
Purity:
|
|
> 98%
|
|
Appearance:
|
|
Off-White
|
|
Chemical Name:
|
|
1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol
|
|
Solubility:
|
|
Up to 37 mM in DMSO
|
|
Synonyms:
|
|
Takeda 779, TAK 779, TAK779
|
|
Storage:
|
|
For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
|
|
References
|
1.
|
Baba M, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. 1999; 96(10): 5698-5703 Pubmed ID: 10318947
|
|
2.
|
Gao P, et al. The unique target specificity of a nonpeptide chemokine receptor antagonist: Selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J Leukoc Biol 2003; 73(2): 273-280 Pubmed ID: 12554804
|
|
3.
|
Kim MB, et al. CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV. Expert Opin Investig Drugs. 2016; 25(12): 13771392. Pubmed ID: 27791451
|
|
4.
|
Ni J, et al. The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function. Br J Pharmacol 2009; 158(8):2046-56. Pubmed ID: 12554804
|
|
Ordering information
|
Catalog No.
|
Product Name
|
Size
|
|
C8257
|
TAK-779
|
2mg, 10mg & 50mg
|
▣ 관련 페이지 ; Cellagen Technology
|
|
|